Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
With our state-of-the-art platforms, Creative Biolabs offers a wide range of ACVR1-targeted recombinant antibodies to clients worldwide, ensuring top-notch quality and comprehensive coverage. We are dedicated to pushing the boundaries of research and exploration, providing outstanding value and unmatched technical assistance to help our clients reach their scientific objectives with maximum efficiency and success.
ACVR1 is a receptor that plays a key role in bone morphogenetic protein signaling. It is linked to fibrodysplasia ossificans progressiva (FOP), a rare disorder of abnormal bone formation. ACVR1 mutations are associated with cardiac and reproductive system abnormalities. Recently, ACVR1 has been implicated as a cancer driver gene in a highly aggressive pediatric brain tumor DIPG. This shows great potential to target ACVR1 to develop therapeutics for cancer therapy.
ALK2; ACTRI; ACVRLK2; ACVR1A; SKR1; TSRI; Activin A receptor type 1/I; Activin receptor-like kinase 2; TGF-B superfamily receptor type I; Serine/threonine-protein kinase receptor R1; EC 2.7.11.30; Hydroxyalkyl-Protein Kinase; EC 2.7.11; FOP.
Cancer-related genes, Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets
Intracellular, Membrane (different isoforms)
Cell type enhanced (Microglial cells)
Immune cell enhanced (T-reg)
Low cell line specificity
Interacts with FKBP1A (PubMed:22484487, Ref.12). Interacts with FCHO1 (PubMed:22484487). Interacts with CLU (PubMed:8555189). Interacts with type II receptors AMHR2 and ACVR2A (PubMed:17911401). Interacts with BMP7 (PubMed:9748228). Interacts with GDF2/BMP9 (PubMed:20628059). Interacts with BMP6 (PubMed:18070108).
Kinase, Receptor, Serine/threonine-protein kinase, Transferase
We are dedicated to advancing research and innovation by providing high-quality anti-ACVR1 recombinant antibodies at great value, along with excellent technical support. Below is a list of recombinant antibodies that target ACVR1. To get all the details and choose the optimal choice, please click on the link supplied.
Cat. No. | Product Name | Target Species | Host Species | Applications |
HPAB-0228-CN | Rat Anti-ACVR1 Recombinant Antibody (clone A2-15A) | Human, Mouse | Rat IgG | ELISA, FC |
HPAB-0709LY | Human Anti-ACVR1 Recombinant Antibody | Human | Humanized IgG1 | ELISA, FC |
HPAB-0708LY | Human Anti-ACVR1 Recombinant Antibody | Human | Humanized IgG1 | ELISA, FC |
HPAB-0233-CN | Human Anti-Acvr1 Recombinant Antibody | Human, Mouse | Humanized IgG1, κ | ELISA, FC |
HPAB-0231-CN | Human Anti-Acvr1 Recombinant Antibody | Human, Mouse | Chimeric (Rat/Human) IgG1, κ | ELISA, FC |
Our dedication is to advance research and development by providing unparalleled product quality and exceptional support, empowering the biopharmaceutical community. By rigorously upholding a comprehensive quality management system, we prioritize client fulfillment. This guarantees that our products not only satisfy but exceed industry standards, thereby simplifying the drug development process and providing clients with superior value.
Fig.1 Anti-ACVR1 Recombinant Antibody in SDS-PAGE.
(Cat# HPAB-0228-CN, Creative Biolabs).
Fig.2 Anti-ACVR1 Recombinant Antibody in HPLC.
(Cat# HPAB-0228-CN, Creative Biolabs).
Our state-of-the-art platform (serum-free) provides a range of services, starting from gene synthesis to the production of high-quality anti-ACVR1 recombinant antibodies. With our extensive knowledge and proficiency in process optimization, we provide efficient and affordable solutions for quickly producing different quantities of antibodies within a short timeframe.
Featured Anti-ACVR1 Recombinant Antibody Production Platforms
Fig.3 Milligram-scale anti-ACVR1 recombinant antibody production.
Fig.4 Gram-scale anti-ACVR1 recombinant antibody production.
Creative Biolabs is committed to providing researchers with a wide range of recombinant antibodies that are both extremely innovative and diverse. Various formats, including full-length, Fab, scFv, etc., are offered in our anti-ACVR1 recombinant antibody products. Meanwhile, we are confident in our ability to provide tailored solutions to address your unique research requirements by drawing on our wealth of knowledge and experience in antibody engineering.
Fig.5 Full-Length Anti-ACVR1 Recombinant Antibody Production and Modalities.
Table 1. ACVR1-targeted drug information.
Company | Highest Phase | Therapeutic Group | Condition |
Cres Pharmaceuticals Cytopia (Gilead) Gilead (Originator) GSK Sierra Oncology (GSK) |
Launched - 2023 |
Hematopoiesis Disorders, Treatment of Non-Small Cell Lung Cancer Therapy Pancreatic Cancer Therapy |
Cancer, lung (non-small cell) (NSCLC), metastatic Cancer, pancreas Cancer, pancreas (ductal adenocarcinoma) Myelofibrosis Myeloproliferative diseases Polycythemia vera Thrombocythemia, essential |
Keros Therapeutics (Originator) | Phase II |
Antianemics Bone, Muscles and Connective Tissue Genetic Disorders, Treatment of |
Fibrodysplasia ossificans progressiva Iron-refractory anemia |
Incyte Novartis (Originator) |
Phase II |
Antianemics Antithrombocythemics Hematopoiesis Disorders, Treatment of Multiple Myeloma Therapy Musculoskeletal and Connective Tissue Diseases, Treatment of Myelodysplastic Syndrome Therapy |
Anemia Fibrodysplasia ossificans progressiva Multiple myeloma Myelodysplasia Myelofibrosis Polycythemia vera Thrombocythemia |
Blueprint Medicines (Originator) Ipsen |
Phase II |
Bone, Muscles and Connective Tissue Genetic Disorders, Treatment of Neurologic Cancer Therapy |
Diffuse intrinsic pontine glioma Fibrodysplasia ossificans progressiva |
BioCryst (Originator) | Phase I | Bone, Muscles and Connective Tissue Genetic Disorders, Treatment of | Fibrodysplasia ossificans progressiva |
Daiichi Sankyo (Originator) Kitasato University (Originator) Saitama Medical University (Originator) |
Preclinical | Bone, Muscles and Connective Tissue Genetic Disorders, Treatment of | Fibrodysplasia ossificans progressiva |
Keros Therapeutics (Originator) | Preclinical | Antianemics | Anemia in chronic kidney disease |
Keros Therapeutics (Originator) | Preclinical | Antianemics | Anemia |
Emory University (Originator) Vanderbilt University (Originator) |
Preclinical | Bone Diseases, Treatment of | Heterotopic ossification |
Oncodesign Services (Originator) | Preclinical |
Antianemics Cancer-Associated Disorders, Treatment of |
Anemia |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
If you would like more information about our anti-ACVR1 recombinant antibody products, please feel free to contact us at your convenience. We are excited to discuss potential partnership opportunities and support your research endeavors.